Yan Leyfman, Co-Founder and Executive Director of MedNews Week, shared on LinkedIn:
“CAR-T therapy is showing us that the immune system can be reset.
But the latest developments in autoimmune disease are a reminder that powerful biology comes with a price. Novartis and Bristol Myers Squibb have temporarily paused multiple autoimmune CAR-T trials after inflammatory safety signals emerged.
For Novartis, three cases of immune effector cell-associated hemophagocytic syndrome (IEC-HS) led to holds across studies of rap-cel in diseases including lupus, myasthenia gravis and multiple sclerosis. Bristol Myers Squibb has also paused enrollment in its zola-cel autoimmune program after observing transient, reversible inflammatory events during safety monitoring.
These programs are among the most exciting developments in autoimmune medicine. CAR-T has the potential to eliminate pathogenic immune cells and produce deep, treatment-free remissions in diseases that have traditionally required lifelong immunosuppression.
But there is an important lesson here:
The goal isn’t simply to make CAR-T cells expand more. It is to make them expand enough, persist enough, and activate precisely enough to reset pathological immunity without creating a new inflammatory problem.
That may ultimately make cell engineering, manufacturing strategy, dose selection, and toxicity prediction just as important as the target itself. Autoimmune CAR-T is still one of the most promising frontiers in cellular therapy. These pauses don’t necessarily change that.
They underscore how much we still have to learn about controlling one of the most powerful therapeutic platforms ever developed.
The next generation of autoimmune cell therapies may not be defined by how aggressively they activate – but by how precisely we can control them.”
You may also be interested in: What Happens If CAR T-Cell Therapy Fails? Relapse, Refractory Disease, and Next Treatment Options
